Divalproex sodium (CAS 76584-70-8)
CAS Number:
76584-70-8
Molecular Weight:
310.4
Molecular Formula:
C16H31NaO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Divalproex sodium is a compound that showcases a unique approach to modulating neurotransmitter activity within the brain, particularly focusing on gamma-Aminobutyric acid (GABA), the central nervous system′s primary inhibitory neurotransmitter. By increasing GABA levels, divalproex sodium contributes to a decrease in neuronal excitability, a mechanism that has been the subject of extensive research within neuropharmacology. This compound is a coordinated complex of valproic acid and sodium valproate, forming a stable salt that enhances the bioavailability and controlled release of valproic acid, a molecule of significant interest in the study of neurochemical regulation and synaptic transmission.
Divalproex sodium (CAS 76584-70-8) References
- Divalproex sodium--review of prophylactic migraine efficacy, safety and dosage, with recommendations. | Landy, SH. and McGinnis, J. 1999. Tenn Med. 92: 135-6. PMID: 10194980
- Divalproex sodium therapy in elderly with dementia-related agitation. | Pratt, CE. and Davis, SM. 2002. Ann Pharmacother. 36: 1625-8. PMID: 12243614
- Divalproex sodium extended-release for the prophylaxis of migraine headache. | Freitag, FG. 2003. Expert Opin Pharmacother. 4: 1573-8. PMID: 12943487
- Divalproex sodium in the treatment of pediatric psychiatric disorders. | Rana, M., et al. 2005. Expert Rev Neurother. 5: 165-76. PMID: 15853487
- Divalproex sodium in the treatment of adults with bipolar disorder. | Davis, LL., et al. 2004. Expert Rev Neurother. 4: 349-62. PMID: 15853533
- Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. | Porsteinsson, AP. 2006. Drugs Aging. 23: 877-86. PMID: 17109566
- Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. | Bond, DJ., et al. 2010. J Affect Disord. 124: 228-34. PMID: 20044142
- Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. | Silberstein, SD., et al. 2012. Neurology. 78: 1337-45. PMID: 22529202
- Preventive Migraine Treatment. | Silberstein, SD. 2015. Continuum (Minneap Minn). 21: 973-89. PMID: 26252585
- Treatment-resistant panic disorder: a systematic review. | Freire, RC., et al. 2016. Expert Opin Pharmacother. 17: 159-68. PMID: 26635099
- Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3. | Wang, ZJ., et al. 2018. CNS Neurosci Ther. 24: 404-411. PMID: 29318784
- Divalproex sodium regulates ataxin-3 translocation likely by an importin α1-dependent pathway. | Wang, Z., et al. 2019. Neuroreport. 30: 760-764. PMID: 31107713
- Drug Treatment of Cluster Headache. | Diener, HC. and May, A. 2022. Drugs. 82: 33-42. PMID: 34919214
- Development and Characterization of Hygroscopicity-Controlled Sustain Release Formulation of Divalproex Sodium. | Adhikari, S., et al. 2022. Turk J Pharm Sci. 19: 422-430. PMID: 36047573
- Divalproex sodium in headache: literature review and clinical guidelines. | Silberstein, SD. 1996. Headache. 36: 547-55. PMID: 8916563
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Divalproex sodium, 100 mg | sc-493285 | 100 mg | $134.00 |